Sponsors (10)
Introduced September 9, 2025 by David Scott · Last progress September 9, 2025
This bill raises awareness and directs modest, targeted resources toward endometrial cancer research and outreach—especially for African‑American women—but its benefits are limited by small authorized funding and non‑binding findings, so meaningful impact hinges on follow‑on implementation and additional appropriations.
Women (especially postmenopausal and African‑American women) will receive targeted outreach and information that increases awareness of endometrial cancer risk and symptoms, which can promote earlier detection.
African‑American women and other racial/ethnic minorities are more likely to be included in outreach and clinical research, improving representation in trials and helping make study findings more applicable to those groups.
Patients and researchers will benefit from increased NIH-funded, coordinated research on endometrial cancer, supporting development of better diagnostics and treatments.
The authorized federal funding is modest (at least $1M/year via NIH) and programs will incur ongoing taxpayer costs while likely being insufficient to rapidly close research and care gaps.
Many provisions are statement-based or naming/authorization-only and do not by themselves guarantee real policy changes, resources, or sustained implementation—so benefits depend on future appropriations and agencies' actions.
Increased awareness and outreach without matching resources could raise demand for diagnostic and treatment services, straining hospital capacity and creating access problems for low‑income and underserved patients.
Based on analysis of 3 sections of legislative text.
Directs NIH to expand and coordinate endometrial cancer research with clinical trial inclusion goals for African‑American women, and directs CDC to run targeted public education; authorizes funding for FY2026–2028.
Expands federal activity on endometrial cancer by directing the NIH to increase, coordinate, and communicate research on the disease and by requiring the CDC to run a public education program with materials targeted to African‑American women and other communities at higher risk. The bill authorizes $1,000,000 per year for NIH for FY2026–2028 and authorizes CDC funding as needed for the same period. The NIH must coordinate related institutes and ensure clinical trial representation of African‑American women in proportion to incidence; CDC must develop and disseminate information on incidence, risk factors, and treatment options and consult HRSA when creating materials.